Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202

With 19.6 yr of follow-up, RTOG 9202 revealed that 28 mo of androgen deprivation therapy (ADT) did not increase cardiovascular mortality versus 4 mo of ADT. For men with baseline cardiovascular disease, longer-term ADT may be associated with increased myocardial infarction mortality. Androgen deprivation therapy (ADT) has been associated with coronary heart disease and myocardial infarction (MI) in prostate cancer patients, but controversy persists regarding its effects on cardiovascular mortality (CVM). We assessed the long-term relationship between ADT and CVM in a prostate cancer randomized trial (NRG Oncology/Radiation Therapy Oncology Group 9202). From 1992 to 1995, 1554 men with locally advanced prostate cancer (T2c–T4, prostate-specific antigen